A Two-Part, Double-Blind, Placebo-Controlled, Phase I Study of the Safety Pharmacokinetics of Single and Multiple Ascending Doses of CT1812 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 05 Dec 2016
At a glance
- Drugs CT 1812 (Primary)
- Indications Cognition disorders
- Focus Adverse reactions
- Sponsors Cognition Therapeutics
- 05 Dec 2016 Data from this trial will be presented at the 9th Clinical Trials on Alzheimer's Disease (CTAD) Meeting, as reported by a Cognition Therapeutics media release.
- 05 Sep 2016 Status changed from recruiting to completed.
- 14 Oct 2015 New trial record